<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">Bile reflux</z:e> contributes to oesophageal injury and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>COX-2 is involved in both <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>; however, the precise mechanisms by which <z:chebi fb="1" ids="3098">bile acids</z:chebi> promote COX-2 expression in the oesophagus are largely unknown </plain></SENT>
<SENT sid="2" pm="."><plain>We analysed the molecular mechanisms that govern <z:chebi fb="0" ids="3098">bile acid</z:chebi>-mediated expression of COX-2 in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: The effects of <z:chebi fb="1" ids="3098">bile acids</z:chebi> on COX-2 expression were analysed in immortalised <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e> cells using immunoblotting and transient transfections </plain></SENT>
<SENT sid="4" pm="."><plain>Pharmacological inhibitors, phospho-specific antibodies, dominant-negative mutants and siRNA techniques were used to identify relevant signalling pathways </plain></SENT>
<SENT sid="5" pm="."><plain>Flow cytometry and reactive oxygen species (ROS) scavengers were used to examine ROS involvement </plain></SENT>
<SENT sid="6" pm="."><plain>Immunohistochemistry was performed on oesophageal mucosa obtained from an established rat model of <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Unconjugated <z:chebi fb="1" ids="3098">bile acids</z:chebi> potently stimulated COX-2 expression and induced AKT and ERK1/2 phosphorylation in concert with COX-2 induction </plain></SENT>
<SENT sid="8" pm="."><plain>These findings were mimicked in the in vivo rat model </plain></SENT>
<SENT sid="9" pm="."><plain>Dominant-negative (DN) AKT and LY294002 (PI3K inhibitor) or U0126 (MEK-1/2 inhibitor) blocked <z:chebi fb="0" ids="16755">chenodeoxycholic acid</z:chebi> (CD) and <z:chebi fb="0" ids="28834">deoxycholic acid</z:chebi> (DC) mediated COX-2 induction </plain></SENT>
<SENT sid="10" pm="."><plain>CD and DC also induced CREB phosphorylation and AP-1 activity </plain></SENT>
<SENT sid="11" pm="."><plain>CREB-specific siRNA and DN AP-1 blocked CD and DC-induced COX-2 induction </plain></SENT>
<SENT sid="12" pm="."><plain>Finally, CD and DC increased intracellular ROS, while ROS scavengers blocked COX-2 induction and the signalling pathways involved </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Unconjugated <z:chebi fb="1" ids="3098">bile acids</z:chebi> induce CREB and AP-1-dependent COX-2 expression in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e> through ROS-mediated activation of PI3K/AKT and ERK1/2 </plain></SENT>
<SENT sid="14" pm="."><plain>This study enhances our understanding of the molecular mechanisms by which <z:chebi fb="1" ids="3098">bile acids</z:chebi> promote the development of oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>